TNYA Stock Price, Chart, Stats & News
Tenaya Therapeutics, Inc. (TNYA) does not currently pay a dividend.
TNYA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -61.66% |
ROE | -85.20% |
D/E | 0.09x |
Interest coverage ratio | – |
TNYA valuation
P/E | – |
P/S | – |
P/B | 0.83x |
P/CF | -1.49x |
P/FCF | -1.61x |
P/OCF | -1.49x |
PEG | -0.05x |
EV multiple | -2.40x |
About
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration.
Similar securities
Based on sector and market capitalization
